Abuse and diversion of buprenorphine sublingual tablets and film-Reference-Cited by-同舟云学术

Abuse and diversion of buprenorphine sublingual tablets and film

Published:2014-07 Issue:1 Volume:47 Page:27-34
ISSN:0740-5472
Container-title:Journal of Substance Abuse Treatment
language:en
Short-container-title:Journal of Substance Abuse Treatment

Author:

Lavonas Eric J.,Severtson S. Geoffrey,Martinez Erin M.,Bucher-Bartelson Becki,Le Lait Marie-Claire,Green Jody L.,Murrelle Lenn E.^ORCID,Cicero Theodore J.^ORCID,Kurtz Steven P.,Rosenblum Andrew,Surratt Hilary L.,Dart Richard C.

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology,Medicine (miscellaneous),Phychiatric Mental Health

Reference32 articles.

1. National Poison Data System (NPDS(R) Reference Manual. Part 2 – System information manual;AAPCC,2007

2. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience;Amass;American Journal on Addictions,2004

3. French field experience with buprenorphine;Auriacombe;American Journal on Addictions,2004

4. Effect of abuse-deterrent formulation of OxyContin;Cicero;New England Journal of Medicine,2012

5. Use and misuse of buprenorphine in the management of opioid addiction;Cicero;Journal of Opioid Management,2007

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. In treating opioid use disorder, does buprenorphine have an increased rate of misuse and diversion compared with buprenorphine–naloxone?;Evidence-Based Practice;2024-08-06

2. Rise in Neonatal Abstinence Syndrome Rate Is Associated with Increase in Buprenorphine Prescription Numbers;Southern Medical Journal;2023-12

3. Guideline No. 443a: Opioid Use Throughout Women’s Lifespan: Fertility, Contraception, Chronic Pain, and Menopause;Journal of Obstetrics and Gynaecology Canada;2023-11

4. Guideline No. 443b: Opioid Use Throughout Women’s Lifespan: Opioid Use in Pregnancy and Breastfeeding;Journal of Obstetrics and Gynaecology Canada;2023-11

5. Directive clinique no 443a : Opioïdes aux différentes étapes de la vie des femmes : Fertilité, contraception, douleur chronique et ménopause;Journal of Obstetrics and Gynaecology Canada;2023-11